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ABSTRACT
CD44 expression is elevated in basal-like breast cancer (BLBC) tissue, and 
correlates with increased efficiency of distant metastasis in patients and experimental 
models. We sought to characterize mechanisms underpinning CD44-promoted 
adhesion of BLBC cells to vascular endothelial monolayers and extracellular matrix 
(ECM) substrates. Stimulation with hyaluronan (HA), the native ligand for CD44, 
increased expression and activation of β1-integrin receptors, and increased α5-
integrin subunit expression. Adhesion assays confirmed that CD44-signalling 
potentiated BLBC cell adhesion to endothelium and Fibronectin in an α5B1-integrin-
dependent mechanism. Co-immunoprecipitation experiments confirmed HA-promoted 
association of CD44 with talin and the β1-integrin chain in BLBC cells. Knockdown of 
talin inhibited CD44 complexing with β1-integrin and repressed HA-induced, CD44-
mediated activation of β1-integrin receptors. Immunoblotting confirmed that HA 
induced rapid phosphorylation of cortactin and paxillin, through a CD44-dependent 
and β1-integrin-dependent mechanism. Knockdown of CD44, cortactin or paxillin 
independently attenuated the adhesion of BL-BCa cells to endothelial monolayers 
and Fibronectin. Accordingly, we conclude that CD44 induced, integrin-mediated 
signaling not only underpins efficient adhesion of BLBC cells to BMECs to facilitate 
extravasation but initiates their adhesion to Fibronectin, enabling penetrant cancer 
cells to adhere more efficiently to underlying Fibronectin-enriched matrix present 
within the metastatic niche.
INTRODUCTION
Extravasation, a critical step within the metastatic 
cascade concerns the arrest and adherence of circulating 
tumor cells (CTCs) on the vascular endothelium within 
distant tissues and organs. This process requires an initial 
arrest on the endothelial cells after which the adherent 
tumor cells traverse the endothelial barrier to gain access 
to the stroma of the underlying tissue. Tumor cells are 
proposed to replicate lymphocyte behavior and roll along 
the endothelial surface prior to attaching firmly to the 
endothelial monolayer [1]. As in lymphocyte adhesion, 
cancer cell extravasation is considered to be dependent 
upon multiple receptor dependent interactions between the 
tumor cell and the endothelium to regulate “rolling” and 
“arrest” on the endothelium, prior to exit of the cell from 
the circulation [2]. Moreover, in order for the invading 
cancer cell to form a clinically-relevant tumor within the 
new tissue, the cancer cell must embed and adhere to the 
substrates present within this new niche.
CD44 is a cell-surface glycoprotein receptor for 
hyaluronan (HA) and is an accepted marker for isolating 
tumourigenic, stem-like breast cancer cells [3, 4]. CD44 
expression is selectively over-expressed in estrogen 
receptor (ER)- and progesterone receptor (PR)-negative 
breast tumors, with enrichment detected in basal-like 
breast cancer (BLBC) [5–7]. Furthermore, CD44-positive, 
stem-like breast cancer cells have been detected within the 
bone marrow of early-stage breast cancer patients [8, 9]. 
Our prior observations demonstrate the importance of 
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CD44 in potentiating the adhesion of representative cell-
based models of BLBC to human bone marrow endothelial 
cells (BMECs) in vitro, indicating a role in supporting 
more efficient extravasation of the cells [10, 11]. 
Moreover, we have shown that CD44 expression increases 
the efficiency of distant metastasis of BLBC cells in vivo 
[7]. Knockdown of CD44 reduced the incidence and 
size of distant metastases resulting from the intracardiac 
injection of BLBC cells, including reduced metastasis in 
the bone, lungs, liver and brain.
CD44 initiated adhesion has been shown to induce 
an integrin receptor-mediated adhesion of T-lymphocytes 
[12, 13], mediated in part through the complexing of 
CD44 with the α4β1-integrin receptor expressed on the 
surface of these cells, and secondly, through a downstream 
promotion of cytoskeletal reorganization [14]. In addition, 
Fujisaki and colleagues determined that CD44 signaling 
could initiate LFA-1 integrin activation to facilitate 
adhesion to endothelium and promote transactivation 
of colorectal cancer cells [15]. The objective of this 
study was to characterize the potential mechanism by 
which CD44 potentiates the adhesion of BLBC cells to 
endothelium and matrix substrates. Here we characterize 
the biochemical and functional importance of a CD44-
induced regulation of β1-integrin receptor expression 
and activation in BLBC cells, resulting in the activation 
of a cortactin-paxillin signal transduction pathway which 
underpins cancer cell adhesion to endothelial cells and 
extracellular matrix (ECM).
RESULTS
CD44 signaling regulates specific α and  
β1-integrin expression
α4β1-integrin receptors play an important role in 
the extravasation of CD44-positive T-lymphocytes in vivo 
[13]. We conducted experiments to characterize the 
relationship between CD44 and integrin subunit expression 
and/or activation, using two representative CD44-
expressing models of BLBC, the MDA-MB-231 and 
Hs578T cell lines [6], and the metastatic prostate cancer 
cell line, PC3 [10]. Stimulation with low molecular weight 
HA (LMW-HA, the signaling ligand for CD44) promoted 
a rapid increase in β1-integrin subunit expression, together 
with an increased pool of activated β1-integrin receptors 
as detected by the B44 and HUTS-4 antibodies (that only 
recognize the active conformation of the β1-integrin) 
[16] (Figure 1A). Furthermore, immunofluorescence-
microscopy confirmed the increased activated β1-integrin 
receptor pool post-HA stimulation in the MDA-MB-231 
cells (Figure 1B). Although the α4-integrin subunit is 
proposed to mediate CD44-promoted adhesion of T-
lymphocytes, we failed to detect expression of the α4-
integrin subunit in BLBC cells by immunocytochemistry, 
immunoblotting or flow cytometry (data not shown). 
Instead, immunoblotting confirmed that HA stimulation of 
BLBC cells promoted a rapid increase in the expression 
of the α5-integrin subunit, concurrent with increased 
expression of the β1-integrin receptor chain (Figure 1A). A 
similar profile of increased expression and activation of the 
α5 and β1-integrin receptors was also detected in CD44-
positive PC3 cells, a bone- metastatic prostate cancer line, 
in response to HA (Supplementary Figure S1A).
Integrin receptors contribute to CD44 promoted 
cell-cell and cell-matrix adhesion
The importance of β1-integrin receptors in 
underpinning CD44-promoted adhesion to BMEC 
monolayers was studied using pan- or selective function-
blocking integrin antibodies. Blockade of all potential 
β1-integrin heterodimers and specific inhibition of the α5β1-
integrin receptor attenuated MDA-MB-231 cell adhesion to 
BMECs by 73% (p < 0.05) and 61% (p < 0.01), respectively. 
In contrast, α2β1-integrin blockade had no effect on MDA-
MB-231 cell adhesion to BMECs (Figure 1C). A similar 
importance of the α5β1-integrin receptor was observed in 
PC3 cells (Supplementary Figure S1B).
CD44 signaling promotes adhesion to fibronectin
The native ECM ligand of the α5β1-integrin 
heterodimer is Fibronectin. Therefore, we determined 
whether CD44-induced activation of this integrin may also 
underpin increased adhesion of MDA-MB-231 cells to this 
ECM substrate. Initial experiments demonstrated that pre-
treatment with the β1-integrin function-blocking antibody 
reduced MDA-MB-231 adhesion to Fibronectin by 84% 
(p < 0.05), confirming the importance of β1-integrin 
receptors in mediating adhesion of CD44-positive MDA-
MB-231 cells to Fibronectin (Figure 1D). The importance 
of CD44 signaling in promoting adhesion to Fibronectin 
was demonstrated in two further assays. Firstly, the 
addition of HA markedly increased the maximal adhesion 
of CD44-positive MDA-MB-231 cells to Fibronectin 
(p < 0.05) (Figure 1E). Furthermore, using stable CD44-
depleted clones of MDA-MB-231 cells, we confirmed 
that loss of CD44 correlated with a significant decrease 
in adhesion potential to Fibronectin, reducing adhesion to 
approximately 20% of control values (p < 0.05) (Figure 1F).
Bone-tropic breast cancer cells have increased 
pools of activated integrin receptors and 
demonstrate increased adhesion properties
CD44 enhances the efficiency of distant metastasis 
in vivo, enabling the formation of tumors in multiple 
secondary sites including the lungs and skeleton. We have 
also observed that bone-tropic MDA-MB-231 (MDA-
MB-231BO) cells expressed elevated levels of CD44 and 
adhered more rapidly to a BMEC monolayer in vitro [7]. 
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Figure 1: HA signaling promotes activation of β1-integrin receptors and promotes β1-integrin-mediated cell 
adhesion. A. Western blots comparing time-dependent expression and changes in integrin activation status of β1-integrin subunits in 
MDA-MB-231 and Hs578T breast cancer cell lines following HA stimulation over a 60 min timecourse. Equal protein loading is confirmed 
by reanalysis of GAPDH expression. B. Representative fluorescence micrographs showing increased cell-surface immunoreactivity 
against the activated β1-integrin conformation (detected by B44 clonal antibody) following HA addition to MDA-MB-231BO cells for 
20 min. Scale bar equivalent to 20 μm. C. Bar graph illustrating how administration of neutralizing antibodies to specific integrin chains 
or heterodimers modulates the efficiency of metastatic MDA-MB-231 cell adhesion over 30 min to a monolayer of human bone marrow 
endothelial cells (hBEMCs). fibronectin-coated plate. Antibodies were used at the concentration of 5 μg/ml, as recommended by the 
manufacturer. D. Bar graph illustrating how administration of a neutralizing antibody against β1-integrin receptors modulates the efficiency 
of metastatic MDA-MB-231 cell adhesion over 30 min to a Fibronectin-coated plate. E. Bar graph illustrating how stimulation of MDA-
MB-231 cells with HA potentiates cell adhesion to Fibronectin over a 30 min timecourse. F. Bar graph illustrating the comparative adhesion 
of parental (Par) and CD44-depleted MDA-231 cells to a Fibronectin-coated plate over a 30 min period. Expression of CD44 levels in shNT 
(non-targeting control) and CD44-targeted (sh#1 and ch#2) cells following stable depletion are presented in McFarlane et al. 2015. All data 
shown in adhesion experiments are a mean ± SEM of at least 3 independent experiments. Statistically significant differences in adhesion 
were determined by a Student’s t-test; *p < 0.05. Immunoblots are representative of three or more independent experiments.
Oncotarget36765www.impactjournals.com/oncotarget
Immunoblotting also reveals these CD44-enriched MDA-
MB-231BO cells to express increased levels of the α5 
and β1-integrin subunit relative to parental cells, and a 
greater pool of activated β1-integrin receptors (assessed 
using HUTS-4 and B44 antibodies) (Figure 2A). This was 
further confirmed by quantitative flow cytometry which 
detected an increased fluorescence intensity to the HUTS-
4 and B44 antibodies in bone tropic cells (average of 33% 
more β1-integrins in the active conformation than parental 
cells) (*p < 0.05) (Figure 2B).
Further analysis was conducted to characterize 
Fibronectin expression between parental and bone homing 
clones of the MDA-MB-231 cell line. Consistent with 
increased CD44 expression and increased activation of 
the β1-integrin receptor pool, MDA-MB-231BO cells 
were shown to have elevated levels of cellular-Fibronectin 
(c-FN) (Figure 2A). Moreover, ELISA analysis confirmed 
a high level of Fibronectin secretion from MDA-MB-231 
cells than BMECs (Figure 2C). MDA-MB-231BO cells 
were also stimulated with HA to determine any association 
of HA with FN expression in these cells. Immunoblotting 
confirmed that HA increased the expression of c-FN 
within these metastatic BLBC cells (Figure 2D).
Consistent with the increased production of 
Fibronectin and increased integrin activation detected on 
bone-tropic MDA-MB-231BO cells, these cells were also 
significantly more adherent to BMECs (reported in [7]) 
and Fibronectin than parental cells at all time points (p < 
0.05) (Figure 2E).
Talin facilitates CD44-induced β1-integrin 
activation in metastatic BLBC cells
Further experiments were conducted to characterize 
the mechanism underpinning CD44-promoted β1-integrin 
activation. Talin is a known interacting protein with the 
cytoplasmic tail of the β1-integrin. Using a series of gene-
targeted siRNA strategies, we observed that knock-down 
of Talin attenuated the level of HA-induced β1-integrin 
activation in MDA-MB-231 cells, and was observed 
to be comparable to that observed in cells depleted of 
CD44 expression. Although HA stimulation increased 
expression of RHAMM, knockdown of this HA receptor 
using siRNA had no effect upon HA-stimulated activation 
of β1-integrin receptors (Figure 3A). In a further series 
of co-immunoprecipitation experiments, conducted in the 
absence and presence of a HA stimulus, we confirmed that 
both β1-integrin and Talin associate with CD44, and that 
the amount of these proteins associated with CD44 was 
potentiated following treatment with HA (Figure 3B). This 
protein complex was further studied under talin-depleted 
conditions. Transfection with talin siRNA reduced the 
level of β1-integrin in the anti-CD44 immunoprecipitate 
(Figure 3C). These results suggest that talin is a key 
intermediate protein facilitating CD44 promoted 
association with β1-integrin receptors and their activation.
Cortactin and paxillin are key downstream 
signaling effectors of CD44/integrin signaling in 
BLBC cells
Immunoblotting was performed to characterize 
HA-induced signaling pathways activated in BLBC cells. 
The non-receptor tyrosine kinases Src and FAK are both 
known substrates of integrin signaling and have confirmed 
roles in modulating cell adhesion, spreading and motility. 
Initial analysis confirmed increased phosphorylation of 
Src and FAK in MDA-MB231BO cells relative to parental 
cells (Figure 4A). Stimulation of MDA-MB-231 with HA 
activated both these kinases; a rapid onset and sustained 
phosphorylation of FAK was detected at multiple sites 
including the auto-phosphorylation site (Tyr397) and the 
integrin-receptor engagement site (Tyr861), the later reaching 
a maximal level of phosphorylation between 30 and 45 min 
post-stimulation (Figure 4B). Increased phosphorylation of 
Src was clearly apparent 10 min after HA stimulation.
We next examined the impact of HA stimulation upon 
the downstream substrates of FAK and Src, the cytoskeletal-
associated proteins cortactin and paxillin. Immunoblotting 
analysis of MDA-MB-231, Hs578T (Figure 4C) and PC3 cells 
(Supplementary Figure S1C) confirmed a time-dependent 
induction of Tyr421 phosphorylation in cortactin following 
addition of exogenous HA. Similarly, HA addition increased 
the phosphorylation of paxillin in each of these BLBC cells. 
Interestingly, we also observed that HA reproducibly increased 
the expression of this cytoskeletal protein in both BLBC cells. 
Immunoblotting confirmed a higher level of constitutive 
phosphorylation of cortactin (Tyr421) and paxillin (Tyr118) 
in the bone-selective metastatic cells relative to the parental 
MDA-MB-231 counterpart (Figure 4D). The mechanism 
underpinning HA-induced phosphorylation of paxillin was 
studied further. MDA-MB-231BO cells were transfected with 
either a CD44-targeted or cortactin siRNA oligonucleotide 
pool. Depletion of CD44 or cortactin each abrogated the HA-
induced phosphorylation of paxillin, detected in response to 
a 10 min exposure to HA (Figure 4E, left and right panels).
The importance of integrin activation to HA-induced 
phosphorylation of cortactin and paxillin was also studied, 
comparing HA-induced cytoskeletal protein phosphorylation 
in the absence and presence of a function-blocking β1-
integrin antibody. Inhibition of β1-integrin signaling 
attenuated HA-induced phosphorylation of cortactin, detected 
10, 20 and 40 min post-addition of the stimulus (Figure 4F).
Cortactin and paxillin underpin CD44-promoted 
adhesion to endothelial monolayers and 
fibronectin
Adhesion assays were performed to characterize the 
relationship of HA-induced signaling events to the CD44- 
and integrin-promoted adhesion of tumor cells to BMECs 
and Fibronectin. Relative to the effect of a non-targeting 
siRNA, knock-down of CD44, cortactin and paxillin 
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Figure 2: Characterization of bone-tropic metastatic breast cancer cells and their adhesion to Fibronectin.  
A. Immunoblots comparing the expression and activation of integrin receptor chains and cellular fibronectin (c-FN) in parental (Par) 
and bone tropic (BO) clones of the MDA-MB-231 cells. Equal protein loading was confirmed by assessment of GAPDH expression. 
Immunoblots are representative of three or more independent experiments. B. Flow cytometry profiles illustrating the elevated expression 
of activated β1-integrin receptor pool using both B44 and HUTS-4 antibodies in MDA-MB-231BO cells relative to parental cells. Grey 
lines represent the isotype control, solid black lines represent profiles on parental MDA-MD-231 cells and the dashed lines represent 
profiles determined on MDA-MD-231BO cells. Inset bar graphs provide quantitative analysis of four independent profiling analyses. 
C. Bar graph presenting a representative profile of elevated FN secretion measured by specific analysis of conditioned media harvested 
from cultures of bone-tropic MDA-MB-231BO cells and BMECs. Data shown is representative of two independent experiments.  
D. Immunoblots comparing time-dependent changes in c-FN expression in MDA-MB-231 breast cancer cell lines following HA stimulation 
over a 60 min timecourse. Equal protein loading is confirmed by reanalysis of GAPDH expression. Immunoblots are representative of three 
or more independent experiments. E. Bar graph illustrating the comparative adhesion of parental (Par) and CD44-enriched bone tropic 
MDA-MB-231BO cells to a Fibronectin-coated plate over a 30 min period. Data shown in adhesion experiments are a mean ± SEM of at 
least 3 independent experiments. Statistically significant differences in adhesion were determined by a Student’s t-test; *p < 0.05.
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Figure 3: Characterization of mechanisms underpinning CD44-promoted integrin activation. A. A panel of immunoblots 
characterizing siRNA-mediated knockdown of Talin (TLN), CD44 or RHAMM expression, and their subsequent effect on HA-induced 
activation of the β1-integrin receptor pool in MDA-MB-231 cells. Cells were stimulated with HA for 2 mins to focus understanding of 
the early events occurring downstream of CD44 activation. B. Immunoblots presenting the analysis of protein lysates harvested by co-
immunoprecipitation experiments using anti-CD44 or anti-IgG antibodies (control). Cells were again stimulated with HA for 2 min to 
characterize the molecular interactions induced immediately downstream of CD44 initiated inside-out signalling. C. Representative blots 
of co-immunoprecipitation experiments characterizing the complex of CD44 with β1-integrins under HA stimulated (20 min) and talin-
depleted conditions. Blots shown are representative of three independent experiments. The experimental design focused on understanding 
the importance of talin depletion on downstream integrin activation, thus introducing a longer incuation time. Immunoblots shown 
throughout the Figure are representative of three or more independent experiments.
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Figure 4: CD44 signaling promotes the phosphorylation of cytoskeletal proteins cortactin and paxillin. A. Panel of 
immunoblots comparing the expression and phosphorylation status of the kinases Src and FAK in the parental and bone-tropic MDA-
MB-231 cell lines. B. Immunoblots comparing the expression and phosphorylation status of Src and FAK following stimulation of MDA-
MB-231BO cells with HA. C. Panel of immunoblots comparing the expression and phosphorylation status of the cytoskeletal proteins 
cortactin and paxillin in MDA-MB-231 (left panel) and Hs578T (right panel) breast cancer cell lines. D. Immunoblot comparing the 
basal expression and phosphorylation status of cortactin and paxillin in parental MDA-MB-231 and bone-tropic MDA-MB-231BO cells. 
E. Panel of immunoblots illustrating the levels of phosphorylation detected in paxillin in response to HA stimulation of MDA-MB-231 
cells in the absence or presence of CD44 (left panel) or the absence and presence of cortactin (CTTN). F. Immunoblots measuring the 
levels of cortactin phospgorylation in HA-stimulated MDA-MB-2331 cells in the absence or presence of a neutralizing antibody to β1-
integrin receptors. Equal protein loading in all immunoblots is confirmed by reanalysis of GAPDH expression. Blots shown in A-F are 
representative of at least three independent experiments.
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expression each reduced the magnitude of adhesion of 
MDA-MB-231 cells to BMECs by 39% (p < 0.05), 33% 
(p < 0.05) and 40% (p < 0.01), respectively (Figure 5A). 
Depletion of CD44, cortactin or paxillin expression also 
diminished adhesion of these cells to Fibronectin by 46%, 
39% and 38% (*p < 0.05), respectively (Figure 5B). 
Treatment with an equivalent concentration of a non-
targeting siRNA had no significant effect on adhesion of 
the cells to Fibronectin or BMECs.
DISCUSSION
Our study provides further characterization of 
the importance of CD44 in augmenting the adhesion 
of malignant cells to the vascular endothelium. Our 
observations also extend our understanding of CD44-
promoted adhesion, revealing a role for this receptor in 
initiating signaling events that promote cell adhesion to a 
matrix substrate Fibronectin, an ECM substrate reported 
to be enriched in the metastatic niche [17]. Using cell-
based models of BLBC, we observe that exogenous HA 
administration initiates a cascade of CD44-dependent 
events that both promote the expression and activation of 
specific integrin receptors to mediate adhesion.
Biochemical and functional experiments demon-
strate a complex inter-relationship of CD44 and the 
Fibronectin pathway. Firstly, immunoblotting and flow 
cytometry experiments confirm HA-induced CD44 
signaling underpins a rapid increase in total and/or 
activated α5- and β1-integrin subunit expression in 
BLBC cells. The rapid changes in integrin expression 
that we observed may relate to characterized effect of 
CD44 signaling in activating downstream Akt, and Erk 
signaling [18], which can regulate the rate of protein 
translation [19, 20]. Secondly, we also confirm that HA 
can increase the synthesis of c-FN in these metastatic 
cells, at a time co-incident with the expression of the 
two integrin chains. This suggests that increased integrin 
receptor activation detected in HA-stimulated cells may 
in part relate to the promotion of “outside-in” signaling 
stemming from de novo Fibronectin synthesis. Thirdly, 
prior studies have reported that the cytoplasmic tail of 
CD44 is required for β1-integrin activation [21]. In co-
immunoprecipitation experiments, we demonstrate 
that exogenous HA increases the association of talin 
with CD44, and the association of CD44 with the β1-
integrin chain. In addition, the formation of the CD44-
integrin-talin complex is enhanced upon exposure to HA. 
Moreover, the depletion of talin attenuated HA-induced 
integrin activation, confirming the role of this protein 
in mediating an “inside-out” HA-induced activation of 
integrin receptors. The association of CD44, talin and β1-
integrin receptors in a potential “ternary” complex may 
explain the rapidity with which HA can induce receptor 
activation and downstream signal transduction in order to 
underpin cellular adhesion and/or motility. Furthermore, 
it is intriguing to note that Fibronectin is also reported to 
be a ligand for CD44 receptors [22], suggesting that HA-
initiated CD44 signalling may also potentiate a direct FN-
CD44 interaction, in addition to stimulating an inside-out 
activation of integrin receptors to enhance FN engagement 
with breast cancer cells. In summary, our data and prior 
published observations suggest that CD44 signaling can 
increase the expression, promote rapid translocation 
[23], and induce activation of integrin receptors [21]. 
This multi-modal regulation of integrin biology would be 
consistent with a strategy employed by a cell to rapidly 
modulate its adhesion to a favorable substrate or interface.
Our observation that CD44 increases α5-integrin 
and β1-integrin expression is consistent with the 
increased efficiency of HA-stimulated malignant cells to 
augment adhesion not only to endothelial cells, but also 
to Fibronectin. Fibronectin is a major constituent of the 
pre-metastatic niche, and is present in both bone and lung 
metastases [17]. Other recent studies associate Fibronectin 
expression with increased tumor aggressiveness and poor 
clinical outcome in invasive breast cancers [24]. The 
capacity of HA and CD44 to promote synthesis of and 
adhesion to Fibronectin would be consistent with a more 
efficient colonization of the metastatic niche by invading 
BLBC cells and the promotion of adhesion-dependent 
outgrowth of secondary tumors. This improved adaptation 
to the microenvironment of the metastatic niche would 
be consistent with our recent observations that CD44 
increases the efficiency of metastasis formed following 
systemic administration of MBA-MB-231 cells [7].
Understanding the downstream signaling 
pathways driving CD44 and integrin promoted adhesion 
to endothelial cells and matrix proteins may identify 
opportunities to prevent and/or reduce the efficiency of 
metastasis outgrowth. Phosphorylation of cortactin and 
paxillin were shown to be important downstream effectors 
underpinning the CD44-initiated, integrin-promoted cell-
cell and cell-matrix adhesion of BLBC cells. Consistent 
with our observation that CD44 promotes distant tumor 
formation within the skeleton in vivo [7], the over-
expression and increased phosphorylation of cortactin 
have also been shown to potentiate the frequency of bone 
metastasis arising from the inoculation of MDA-MB-231 
breast cancer cells into athymic nude mice [25]. Moreover, 
our observation that two substrates of Src signaling, i.e. 
cortactin and paxillin, underpin CD44-promoted adhesion 
and the positive correlation of CD44 to distant metastasis, 
is intriguing given the enrichment of Src activity detected 
in breast cancers with high propensity to spread to the 
bone [26, 27].
This report provides further molecular evidence to 
support experimental data linking CD44 to a more efficient 
metastasis of breast cancer in vivo [7, 28]. Studies from our 
research group alone provide evidence that not only does 
CD44 enable adhesion to distant endothelium and secondary 
tumor niches by promoting integrin-dependent signaling, 
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Figure 5: CD44 promoted cytoskeletal signaling mediates adhesion to endothelial monolayers and Fibronectin-
enriched matrices. A. Bar graph illustrating the effect of siRNA-mediated repression of CD44, cortactin (CTTN) or paxillin upon 
the adhesion of MDA-MB-231BO cells to BMECs. B. Bar graph illustrating the effect of siRNA-mediated repression of CD44, cortactin 
(CTTN) or paxillin (PXN) upon the adhesion of MDA-MB-231 cells to Fibronectin. The final concentration of siRNA-oligonucleotides 
used in all transfection reactions was 10 nM. Adhesion was measured 30 min post-addition of the cells to the substrate. All data is the mean 
± S.E.M of three at least three independent experiments (*p < 0.05; calculated by two-tailed t-test analysis).
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CD44 also facilitates local invasion through up-regulation of 
uPA, metalloproteinase and cathepsin proteolytic activity in 
BLBC cells [6]. Furthermore, we and others have detected 
elevation of CD44 in the poor prognostic basal subtype of 
breast cancer or stem-like tumor cells that have disseminated 
to the bone marrow [5–8]. In contrast, other recent 
immunohistochemical studies suggest that CD44 expression 
correlates with a favorable patient outcome [29]. Therefore, 
given the known complexity of this glycoprotein with respect 
to its structural biology and its biological diversity, and the 
distinct clinical outcomes that have been reported, CD44 
is unlikely to have clinical utility as a singular prognostic 
marker. However, future studies should address whether the 
analysis of CD44, increased FN and α5β1-integrin receptor 
expression and a cohort of other CD44-affiliated metastasis-
associated genes (e.g. cortactin, MT1-MMP, cathepsin K, 
and uPA), may provide a more robust prognostic signature 
to differentiate clinical outcome and predict patient outcome.
In summary, we demonstrate the capacity of HA-
induced CD44-mediated signaling to increase the efficiency 
of integrin-mediated adhesion of metastatic breast cancer 
cells to vascular endothelium and Fibronectin-enriched 
matrices. The capacity to increase cell-cell and cell-matrix 
adhesion is consistent with our observations that CD44 
increases the efficiency of distant metastasis of basal-like 
breast cancer in vivo. Further investigations are required 
to address the endothelial cell counter-ligands that engage 
the activated integrin-receptors detected on the surface of 
these FN-secreting, CD44-enriched BLBCs to facilitate 
endothelial cell arrest and adhesion.
MATERIALS AND METHODS
Antibodies and reagents
Primary antibodies for anti-CD44 (R&D systems, 
UK), anti-cortactin (Upstate Biotechnology, NY, USA), 
anti-paxillin, anti-phosphoTyr118-paxillin were obtained 
from Cell Signaling Technology (Beverly, MA), while 
anti-α5β1-integrin, anti-α2β1-integrin, anti-β1-integrin, 
activated-β1-integrin conformations (B44 and HUTS-4), 
cellular Fibronectin and phosphoTyr421-cortactin were 
purchased from Millipore (Watford, UK). HRP-conjugated 
secondary antibodies were obtained from Amersham, UK 
and Hyaluronan (MW220 kDa) from Lifecore Biomedical 
(MN, USA). Cells were stimulated with 100 μg/ml HA for 
indicated times. All other reagents were purchased from 
Sigma (Poole, UK) unless otherwise stated.
Cell culture
Authenticated MDA-MB-231, MDA-MB-157 
and PC3 lines were obtained from ATCC (Teddington, 
UK). Hs578T cells were kindly provided by Dr Paul 
Mullan (Centre for Cancer Research and Cell Biology, 
Queen’s University Belfast). The highly invasive clone, 
MDA-MB-231BO was provided complete with matched 
parental cells by Prof. Toshiyuki Yoneda (University 
of Osaka, Japan) [30] and were cultured in DMEM 
supplemented with 10% v/v foetal calf serum (FCS) 
(Invitrogen™ Life Technologies, Paisley, UK). CD44 
depleted luciferase-expressing MDA-MB-231 cells from 
Caliper Life Sciences (Cheshire, UK) were generated in 
our laboratory by stable transfection with CD44 shRNA 
or non-targeting shRNA control as previously described 
[7] and cultured in DMEM supplemented with 10% v/v 
FCS, 0.2 μg/ml puromycin. All cell lines were grown to 
70% confluence prior to experimentation. Human bone 
marrow endothelial cells (BMEC) were provided by 
Dr Babette Weksler (Cornell University, NY) and cultured 
as previously described [10].
Invasion and adhesion assays
Cell invasion and adhesion were assayed as 
described previously [6, 11].
Flow cytometry
Cells were fixed in 1% paraformaldehyde and 
stained with HUTS4 and B44 antibodies according to 
manufacturer’s instructions followed by detection with 
FITC-conjugated secondary antibody (Dako, Ely. UK). 
Data was acquired with a FACSCantoII (BD Biosciences, 
Oxford, UK) and analysed using FlowJo software. Isotype-
controls were used to determine baseline parameters in 
these experiments.
SDS-PAGE and western-blotting
Cell lysates (20 μg) were separated by SDS-PAGE 
and transferred onto immobilon-P PVDF membranes 
(Millipore, Billerica, MA, USA). Membranes were 
blocked for 1 h at RT in Tris-buffered saline/0.1% 
Tween-20 (TBS-T) containing 5%(v/v) dried milk. 
Incubation with primary antibody was carried out at 4°C 
overnight. Membranes were washed three times in TBS-T 
and then incubated for 1 h with the appropriate horse-
radish peroxidase (HRP)-labeled secondary antibody. 
Following three washes in TBS-T, immunoreactivity was 
detected using SuperSignal West Pico Chemiluminescent 
Substrate (Pierce Biotechnology, Rockford, IL, USA) 
followed by exposure to X-ray film. Note, for detection 
of activated β1-integrins, lysates were electrophoresed on 
7.5% SDS-PAGE gels under non-reducing conditions as 
detailed previously [16].
Co-immunoprecipitation
1 mg cell lysate was incubated overnight at 4°C with 
5 μg of mouse anti-CD44 or IgG2A (50 mM Tris [pH 8.0], 
5 mM EDTA, 1% CHAPS, protease inhibitor cocktail). 
Immune complexes were precipitated using 20 μL sheep 
Oncotarget36772www.impactjournals.com/oncotarget
anti-mouse dynabeads (Invitrogen) for 2 h followed by 
three washes with immunoprecipitation buffer. Eluted 
samples and analyzed by Western-blotting for CD44, 
β1-integrin or Talin.
Fluorescence microscopy
Cells fixed with 4% paraformaldehyde were stained 
according to antibody manufacturer’s instructions and 
detected with TRITC–conjugated donkey anti-mouse 
(Jackson ImmunoResearch, Newmarket, UK). Nuclei 
were counterstained with 300 nmol/L DAPI (Molecular 
Probes, Life Technologies, Paisley, UK). Slides were 
mounted using Vectashield (Vector Laboratories, 
Peterborough, UK) and viewed with LSM 510 META 
NLO confocal microscope (Zeiss, Cambridge, UK). 
Isotype-controls were used to set baseline paremeters in 
these experiments.
RNAi suppression of CD44, cortactin and 
paxillin
CD44/cortactin/paxillin expression was suppressed 
using validated RNAi oligonucleotide pools (SMARTpool®, 
GE Dharmacon, Lafayette, CO). Cells were transfected 
using DharmaFECT2 for 72 h prior to experimentation.
Fibronectin ELISA
Fibronectin ELISA was obtained from Millipore and 
was used according to manufacturer’s instructions.
Statistical analysis
For all in vitro analysis, significance was analyzed 
using a two-tailed Student’s t-test. Analysis was performed 
by comparing interventional arms to both untreated/
unstimulated controls and the isotype-control arms, 
although statistical data reported in the manuscript relates 
to the isotype-control or vehicle control arms.
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